December 20th 2024
The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
ten23 Expands Sterile Manufacturing Capacity at VIVA 1 Facility
September 6th 2023Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
AGC Biologics Partners with Asahi Kasei on Clinical Antibody Project
August 16th 2023The agreement also lists that AGC Biologics will leverage the company’s monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei drug substance.